Last reviewed · How we verify
Metronidazole (male partner)
Metronidazole (male partner) is a Nitroimidazole antibiotic Small molecule drug developed by University of Alabama at Birmingham. It is currently in Phase 3 development for Bacterial vaginosis (male partner treatment to prevent reinfection), Trichomoniasis (male partner treatment).
Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being reduced in anaerobic environments.
Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being reduced in anaerobic environments. Used for Bacterial vaginosis (male partner treatment to prevent reinfection), Trichomoniasis (male partner treatment).
At a glance
| Generic name | Metronidazole (male partner) |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Nitroimidazole antibiotic |
| Target | Bacterial/parasitic DNA |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Metronidazole is activated by anaerobic organisms and generates cytotoxic free radicals that damage microbial DNA, leading to cell death. It is effective against anaerobic bacteria and certain parasites. In this Phase 3 trial context (male partner treatment), it is likely being used to treat bacterial vaginosis or trichomoniasis in the female partner's male sexual contact to prevent reinfection.
Approved indications
- Bacterial vaginosis (male partner treatment to prevent reinfection)
- Trichomoniasis (male partner treatment)
Common side effects
- Metallic taste
- Nausea
- Headache
- Gastrointestinal upset
- Dark urine
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole (male partner) CI brief — competitive landscape report
- Metronidazole (male partner) updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI
Frequently asked questions about Metronidazole (male partner)
What is Metronidazole (male partner)?
How does Metronidazole (male partner) work?
What is Metronidazole (male partner) used for?
Who makes Metronidazole (male partner)?
What drug class is Metronidazole (male partner) in?
What development phase is Metronidazole (male partner) in?
What are the side effects of Metronidazole (male partner)?
What does Metronidazole (male partner) target?
Related
- Drug class: All Nitroimidazole antibiotic drugs
- Target: All drugs targeting Bacterial/parasitic DNA
- Manufacturer: University of Alabama at Birmingham — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial vaginosis (male partner treatment to prevent reinfection)
- Indication: Drugs for Trichomoniasis (male partner treatment)
- Compare: Metronidazole (male partner) vs similar drugs
- Pricing: Metronidazole (male partner) cost, discount & access